You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Efficacy of adjuvant weight loss medication after bariatric surgery
|
|---|---|
| Published in |
Surgery for Obesity and Related Diseases, October 2017
|
| DOI | 10.1016/j.soard.2017.10.002 |
| Pubmed ID | |
| Authors |
Zubaidah Nor Hanipah, Elie C. Nasr, Emre Bucak, Philip R. Schauer, Ali Aminian, Stacy A. Brethauer, Derrick Cetin |
| Abstract |
Some patients do not achieve optimal weight loss or regain weight after bariatric surgery. In this study, we aimed to determine the effectiveness of adjuvant weight loss medications after surgery for this group of patients. An academic medical center. Weight changes of patients who received weight loss medications after bariatric surgery from 2012 to 2015 at a single center were studied. Weight loss medications prescribed for 209 patients were phentermine (n = 156, 74.6%), phentermine/topiramate extended release (n = 25, 12%), lorcaserin (n = 18, 8.6%), and naltrexone slow-release/bupropion slow-release (n = 10, 4.8%). Of patients, 37% lost>5% of their total weight 1 year after pharmacotherapy was prescribed. There were significant differences in weight loss at 1 year in gastric banding versus sleeve gastrectomy patients (4.6% versus .3%, P = .02) and Roux-en-Y gastric bypass versus sleeve gastrectomy patients (2.8% versus .3%, P = .01).There was a significant positive correlation between body mass index at the start of adjuvant pharmacotherapy and total weight loss at 1 year (P = .025). Adjuvant weight loss medications halted weight regain in patients who underwent bariatric surgery. More than one third achieved>5% weight loss with the addition of weight loss medication. The observed response was significantly better in gastric bypass and gastric banding patients compared with sleeve gastrectomy patients. Furthermore, adjuvant pharmacotherapy was more effective in patients with higher body mass index. Given the low risk of medications compared with revisional surgery, it can be a reasonable option in the appropriate patients. Further studies are necessary to determine the optimal medication and timing of adjuvant pharmacotherapy after bariatric surgery. |
X Demographics
The data shown below were collected from the profiles of 27 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 10 | 37% |
| Spain | 2 | 7% |
| Brazil | 2 | 7% |
| United Kingdom | 2 | 7% |
| Canada | 1 | 4% |
| Kuwait | 1 | 4% |
| Colombia | 1 | 4% |
| Japan | 1 | 4% |
| Argentina | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 6 | 22% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 44% |
| Practitioners (doctors, other healthcare professionals) | 7 | 26% |
| Scientists | 6 | 22% |
| Science communicators (journalists, bloggers, editors) | 2 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 102 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 102 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 14 | 14% |
| Other | 12 | 12% |
| Researcher | 10 | 10% |
| Student > Postgraduate | 9 | 9% |
| Student > Bachelor | 8 | 8% |
| Other | 15 | 15% |
| Unknown | 34 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 33% |
| Biochemistry, Genetics and Molecular Biology | 5 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Agricultural and Biological Sciences | 3 | 3% |
| Sports and Recreations | 3 | 3% |
| Other | 11 | 11% |
| Unknown | 42 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 September 2023.
All research outputs
#1,488,840
of 25,882,826 outputs
Outputs from Surgery for Obesity and Related Diseases
#124
of 1,970 outputs
Outputs of similar age
#29,215
of 336,795 outputs
Outputs of similar age from Surgery for Obesity and Related Diseases
#9
of 63 outputs
Altmetric has tracked 25,882,826 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,970 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.4. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 336,795 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 63 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.